Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Matthew Mossanen is a urologic oncologist and health services researcher whose work centers on improving surgical quality and value in the treatment of genitourinary cancers, particularly bladder, prostate, and testicular malignancies. His most cited study, with 83 citations, revealed significant variations in the costs of radical cystectomy for bladder cancer across the United States, highlighting opportunities for reducing wasteful spending without compromising outcomes. Dr. Mossanen has also demonstrated that robotic-assisted radical cystectomy is associated with lower perioperative mortality in octogenarians, advancing the evidence for minimally invasive approaches in elderly patients. He has defined key factors associated with high-quality cystectomy surgery through analysis of the British Association of Urological Surgeons registry, and has examined physician and facility drivers of spending variation in locoregional prostate cancer. More recently, he has pioneered novel technologies, including an MR-guided implantable microdevice for testing systemic therapy agents in situ within prostate tumors, and has reported contemporary perioperative outcomes of open retroperitoneal lymph node dissection for testicular cancer. His work during the COVID-19 pandemic further assessed shifts in ambulatory urologic oncology surgeries. Dr. Mossanen’s research directly informs surgical decision-making, healthcare policy, and cost-effective cancer care.